Skip to content

SPYRE THERAPEUTICS, INC.

SYRE

CIK 0001636282

← back to feed
Revenue (TTM)
$0
Q1 Apr 2026
Net Income (TTM)
−$161.68M
+25.4% YoY Q1 Apr 2026
EPS Diluted (TTM)
$1.63
+155.3% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$146.54M
Q1 Apr 2026
Cash
$97.19M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
86.84M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings